Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group-Reference-Cited by-同舟云学术

Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group

Published:2017 Issue:1 Volume:57 Page:17-27
ISSN:0470-8105
Container-title:Neurologia medico-chirurgica
language:en
Short-container-title:Neurol. Med. Chir.(Tokyo)

Author:

AOKI Tomokazu¹,ARAKAWA Yoshiki²,UEBA Tetsuya³,ODA Masashi⁴,NISHIDA Namiko⁵,AKIYAMA Yukinori⁶,TSUKAHARA Tetsuya¹,IWASAKI Koichi⁵,MIKUNI Nobuhiro⁶,MIYAMOTO Susumu²

Affiliation:

1. Department of Neurosurgery, National Hospital Organization, Kyoto Medical Center

2. Department of Neurosurgery, Graduate School of Medicine, Kyoto University

3. Department of Neurosurgery, Kochi Medical School, Kochi University

4. Department of Neurosurgery, National Hospital Organization, Himeji Medical Center

5. Department of Neurosurgery, Kitano Hospital Medical Research Institute

6. Department of Neurosurgery, Sapporo Medical University

Publisher

Japan Neurosurgical Society

Subject

Neurology (clinical),Surgery

Link

https://www.jstage.jst.go.jp/article/nmc/57/1/57_oa.2016-0162/_pdf

Reference42 articles.

1. 1) Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987–96, 2005

2. 2) Le Rhun E, Taillibert S, Chamberlain MC: Anaplastic glioma: current treatment and management. Expert Rev Neurother 15: 601–620, 2015

3. 3) Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27: 5874–5880, 2009

4. 4) Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709–722, 2009

5. 5) Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370: 699–708, 2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Reoperation Timing on Survival among Recurrent Glioblastoma Patients: A Retrospective Multicentric Descriptive Study;Cancers;2023-04-28

2. Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era;Biomedicines;2022-08-09

3. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults;Journal of Neuro-Oncology;2022-02-23

4. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance;Cancer Science;2021-10-02

5. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis;Cochrane Database of Systematic Reviews;2021-01-05